2463 Schedule of therapeutic substances

  • STATE HORSE RACING COMMISSION

    Schedule of Therapeutic Substances

    [43 Pa.B. 7612]
    [Saturday, December 28, 2013]

     The State Horse Racing Commission (Commission), in accordance with the Race Horse Industry Reform Act (4 P. S. §§ 325.101—325.402), and more specifically 58 Pa. Code § 163.304 (relating to substances of therapeutic value), adopts the schedule of therapeutic medications established by the Racing Medication and Testing Consortium (RMTC) and adopted by the Association of Racing Commissioners International (ARCI).

     Under 58 Pa. Code § 163.304, the Commission may approve and adopt by reference the RMTC/ARCI schedule of therapeutic medications and their respective threshold levels. On July 11, 2013, at its public meeting the Commission formally approved the schedule set forth as follows. This schedule shall take effect on January 1, 2014. The Commission will publish any subsequent amendments or additions to the RMTC/ARCI therapeutic schedule.

     The Commission did not engage in an independent testing evaluation of the administration times or administration dosage for these medications. Individuals using the enumerated therapeutic medications are encouraged to seek the advice of their respective Veterinarians.

    RMTC

    Controlled Therapeutic Medications

    Substance Restricted
    Administration Time
    Threshold Route of Administration Experimental Administration Dosage
    Acepromazine 48 hours HEPS—10 ng/mL of urine Intravenous 0.05 mg/kg
    Betamethasone 7 days 10 pg/mL in plasma or
    serum
    slntra-articular 9 mg total in one articular space
    Butorphanol 48 hours Free butorphanol—
    2 ng/mL of plasma, or
    Total butorphanol—
    300 ng/mL of urine.
    Intravenous 0.1 mg/kg
    Clenbuterol 14 days 140 pg/mL of urine or
    LOD in plasma
    Oral 0.8 mcg/kg
    Dantrolene 48 hours 5-OH dantrolene—
    0.1 ng/mL of plasma
    or serum
    Oral 500 mg total dose
    Detomidine 72 hours 1 ng/mL of carboxy-
    detomidine in
    urine; LOD for detomidine
    in plasma
    Sublingual detomidine (Domosedan gel) 40 mcg/kg
    Dexamethasone 72 hours 5 pg/mL of plasma or
    serum
    Oral, Intravenous,
    IM
    0.05 mg/kg
    Diclofenac 48 hours 5 ng/mL of plasma or
    serum
    Topical 5" ribbon of Surpass every 12 hours to one site
    DMSO 48 hours 10 mcg/mL of plasma or serum Oral or IV
    Firocoxib 14 days 20 ng/nriL of plasma or serum Oral 0.1 mg/kg for 4 days
    Flunixin 24 hours 20 ng/mL of plasma or
    serum
    Intravenous 1.1 mg/kg
    Furosemide 4 hours 100 ng/mL in blood and
    urine specific gravity
    < 1.010
    Intravenous Up to 500 mg total dose
    Glycopyrrolate 48 hours 3 pg/mL of plasma or
    serum
    Intravenous1 mg total dose
    Ketoprofen24 hours10 ng/mL of plasma or
    serum
    Intravenous2.2 mg/kg
    Lidocaine (interim)72 hours20 pg/mL of total 30H-lidocaine in plasma Subcutaneous—
    distal limb
    200 mg of lidocaine Hydrochloride salt
    Mepivacaine 72 hours 30H-mepivacaine—10 ng/mL in urine or mepivacaine at LOD in plasma Subcutaneous—
    distal limb
    0.07 mg/kg
    Methocarbamol48 hours 1 ng/mL of plasma or
    serum
    IV or Oral 15 mg/kg IV, 5 g oral
    Methylprednisolone 7 days 100 pg/mL in plasma or serum Intra-articular 100 mg total in one articular space *
    Omeprazole24 hours omeprazole sulfide—
    1 ng/mL in urine
    Oral 3.9 mg/kg
    Phenylbutazone 24 hours 2 mcg/mL of plasma or
    serum
    Intravenous 4 mg/kg
    Prednisolone48 hours 1 ng/mL of plasma or serum Oral1 mg/kg
    Procaine penicillinTime of entry 25 ng/mL of plasma Intra-muscular
    Triamcinolone  acetonide 7 days 100 pg/mL of plasma or serum Intra-muscular9mg total in one articular space
    Xylazine (interim)48 hours 0.01 ng/mL of plasma Intravenous

     * Note: At the 100 mg experimental dose, the safe time for administration to meet the 100 pg/mL threshold was 21 days—the 7 day withdrawal time anticipates that protocols vary and a smaller dose may be utilized which may allow plasma concentrations to fall below the threshold more quickly.

    WALTER REMMERT, 
    Acting Executive Secretary

    [Pa.B. Doc. No. 13-2463. Filed for public inspection December 27, 2013, 9:00 a.m.]

Document Information